Pancreatic Cancer Research

ResearcherBeijing University of Chinese MedicineNo recent work listed

Jie He

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-0285-5403; OpenAlex author ID A5100685161. Sources: OpenAlex.

Their work

Papers
3 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
0
Collaborators
8
Papers, trials and grants by year

2022: 1 paper · 2023: 2 papers

Papers 3

  1. A Novel HRD Signature Is Predictive of FOLFIRINOX Benefit in Metastatic Pancreatic Cancer. Co-author DOI 10.1093/oncolo/oyad178↗
  2. Systemic Analyses of Cuproptosis-Related lncRNAs in Pancreatic Adenocarcinoma, with a Focus on the Molecular Mechanism of LINC00853. Last author DOI 10.3390/ijms24097923↗
  3. Efficacy and safety of traditional Chinese medicine for the treatment of pancreatic cancer: An overview of systematic reviews and meta-analyses. Last author DOI 10.3389/fphar.2022.896017↗

Closest collaborators

The 8 strongest of 8 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Leifeng Chen · 1 shared paper, 2023 · strength 0.22
  2. Jing Wang · 1 shared paper, 2022 · strength 0.20
  3. Ruoqi Zhang · 1 shared paper, 2022 · strength 0.20
  4. Peitong Zhang · 1 shared paper, 2022 · strength 0.20
  5. Ethan S. Sokol · 1 shared paper, 2023 · strength 0.15
  6. Kuei‐Ting Chen · 1 shared paper, 2023 · strength 0.15
  7. Michael Jon Pishvaian · 1 shared paper, 2023 · strength 0.15
  8. Aatur Dilip Singhi · 1 shared paper, 2023 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.